Literature DB >> 27668396

Radical Hysterectomy Plus Concurrent Chemoradiation/Radiation Therapy Is Negatively Associated With Return to Work in Patients With Cervical Cancer.

Keiichiro Nakamura1, Hisashi Masuyama, Naoyuki Ida, Tomoko Haruma, Tomoyuki Kusumoto, Noriko Seki, Yuji Hiramatsu.   

Abstract

OBJECTIVE: Cervical cancer is one of the most common malignant diseases in working-age women. This study investigated the influence of adverse effects of various treatment modalities on return to work in women with cervical cancer.
METHODS: Questionnaires and clinical data from medical records of 97 patients with early stage (stages I and II) cervical cancer were collected and assessed by treatment received. The following treatment groups were analyzed for correlations between time to return to work and various adverse effects: radical hysterectomy (RH) alone, RH group (n = 29); concurrent chemoradiation therapy (CCRT)/radiation therapy (RT) alone, CCRT/RT group (n = 21); and RH + CCRT/RT group (n = 47). The χ test was used to determine the significance of the correlations.
RESULTS: The mean age at the time of diagnosis was 43.0 years and the average interval since treatment was 4.5 years. The RH + CCRT/RT group was the most strongly negatively associated with return to work in employed patients who had undergone CCRT/RT group of cervical cancer (P = 0.012). There was a significant association between failure to return to work and lower extremity lymphedema (P = 0.049). A more than-6-month interval between treatment and return to work and reduced personal income occurred in a significantly higher percentage of patients in the RH + CCRT group than in the CCRT/RT group (P = 0.034 and P = 0.034).
CONCLUSIONS: Of the treatments assessed, RH + CCRT/RT has the greatest negative effect on return to work in women with cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27668396     DOI: 10.1097/IGC.0000000000000840

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  3 in total

1.  Therapeutic Delivery of miR-29b Enhances Radiosensitivity in Cervical Cancer.

Authors:  Tingting Zhang; Xiang Xue; Huixia Peng
Journal:  Mol Ther       Date:  2019-04-11       Impact factor: 11.454

2.  Employment disruption among women with gynecologic cancers.

Authors:  Roni Nitecki; Shuangshuang Fu; Kirsten A Jorgensen; Lauren Gray; Carolyn Lefkowits; Benjamin D Smith; Larissa A Meyer; Alexander Melamed; Sharon H Giordano; Pedro T Ramirez; Jose Alejandro Rauh-Hain
Journal:  Int J Gynecol Cancer       Date:  2021-11-16       Impact factor: 4.661

3.  Return to Work, Fatigue and Cancer Rehabilitation after Curative Radiotherapy and Radiochemotherapy for Pelvic Gynecologic Cancer.

Authors:  Eva Meixner; Elisabetta Sandrini; Line Hoeltgen; Tanja Eichkorn; Philipp Hoegen; Laila König; Nathalie Arians; Jonathan W Lischalk; Markus Wallwiener; Ilse Weis; Daniela Roob; Jürgen Debus; Juliane Hörner-Rieber
Journal:  Cancers (Basel)       Date:  2022-05-08       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.